

1400 West Main Street, Bldg. 1, Suite D

Bellevue, Ohio 44811

Phone: 419.484.5970 Fax: 419.484.5917

## **Medication Management Clinic Patient Referral Form**

PATIENT INFORMATION	First Name:	Date: MI: DOB:
Patient Last Name:Patient Home Phone Number: ()	First Name:	MI: DOB:
Patient Address: Street Address		
City:	State:	Zip:
INSURANCE INFORMATIO		
Is this patient covered by insurance? Yes		ice card(s) / ID Lacii visit)
Please indicate Primary Insurance:		
Subscriber's Name:		
Subscriber's Name: DOB: Patient's relationship to subscriber: □ Self □ Spo	Group #:	Policv #:
Patient's relationship to subscriber:	ouse Child Other:	
Name of Secondary Insurance:		
Subscriber's Name:		
SS#: DOB:	Group #:	Policy #:
Subscriber's Name:	ouse $\square$ Child $\square$ Other:	
INDICATION	ON/GOALS (Check all tha	at apply)
☐ Atrial Fibrillation/Flutter (☐ Chronic☐ New		
		n DVT, recurrent
☐ Treatment of Venous Thromboembolism (DVT	☐ Pulmonary embo	olism (PE) 1st
□ Prevention of Venous Thromboembolism →	☐ Post general sur	gery Dost orthopedic surgery
		cological/urological surgery
□ Valve Replacement → □ Mitral (type	) →	Aortic (type)
Mechanical	$\rightarrow$	☐ Bioprosthetic
□ Post Mycocardial Infarction → □ Warfarin on	ly	
Comprehensive Medication Review:		Utner:
GOALS OF THERAPY	A	nticipated Duration of Anticoagulation
Target INR Range:		3 months
2-3 (ACCP recommended for VTE (DVT, PE) A. F		6 months
$\square$ 2.5-3.5 (specific types of mechanical valves or ac		Indefinite
risk factors for thromboembolism:	)	Other:
		Coagulation Defects
Recent Warfarin History		☐ Antithrombin deficiency
It will be very helpful to have results of most recent	INR's and dosage:	☐ Protein C deficiency
Current dose and schedule:		☐ Protein S deficiency
INR/Date://	_/	☐ Factor V Leiden
Any other comments		☐ Antiphospholipid syndrome ☐ 20210A mutation or Other
Any other comments:		20210A mutation of Other
BUVOLOLAN	ALITHODIZATION COST	DEFEDRAL
This serves as referral to <b>The Bellevue Hospital M</b>	AUTHORIZATION FOR F	
adjust Warfarin, Low Molecular Weight Heparin, Vita		ne and conaborative Agreement to monitor and
		(Please print) <b>Date:</b>
Physician Name:Physician Phone #: ()	Fax: #: ( )	(i loade plint) bates
Note: Patient to be followed by physician office until		ion Management Clinic.
***Please include most recent History & Physica		
•		
▶ PHYSICIAN SIGNATURE:		

Patient will be managed and dosed according to the most recent American College of Chest Physicians Clinical Practice Guidelines. If Referring Physician not available in emergent situations, the Clinic Medical Director may be contacted to help assess and treat patient. Fax completed form to (419) 484-5917.